Distinguishing benign and malignant breast tumors: Preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial

Anna G. Sorace, Savannah C. Partridge, Xia Li, Jack Virostko, Stephanie L. Barnes, Daniel S. Hippe, Wei Huang, Thomas E. Yankeelov

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Comparative preliminary analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data collected in the International Breast MR Consortium 6883 multicenter trial was performed to distinguish benign and malignant breast tumors. Prebiopsy DCE-MRI data from 45 patients with suspicious breast lesions were obtained. Semiquantitative mean signal-enhancement ratio (SERmean) was calculated for all lesions, and quantitative pharmacokinetic, parameters Ktrans, kep, and ve, were calculated for the subset with available T1 maps (n=35). Diagnostic performance was estimated for DCE-MRI parameters and compared to standard clinical MRI assessment. Quantitative and semiquantitative metrics discriminated benign and malignant lesions, with receiver operating characteristic area under the curve (AUC) values of 0.71, 0.70, and 0.82 for Ktrans, kep, and SERmean, respectively (p<0.05). At equal 94% sensitivity, the specificity and positive predictive value of SERmean (53% and 63%, respectively) and K trans (42% and 58%) were higher than clinical MRI assessment (32% and 54%). A multivariable model combining SERmean and clinical MRI assessment had an AUC value of 0.87. Quantitative pharmacokinetic and semiquantitative analyses of DCE-MRI improves discrimination of benign and malignant breast tumors, with our findings suggesting higher diagnostic accuracy using SERmean. SERmean has potential to help reduce unnecessary biopsies resulting from routine breast imaging.

Original languageEnglish (US)
Article number011019
JournalJournal of Medical Imaging
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Breast
Magnetic Resonance Imaging
Breast Neoplasms
Area Under Curve
Pharmacokinetics
ROC Curve
Multicenter Studies
Biopsy

Keywords

  • breast cancer
  • dynamic contrast-enhanced MRI
  • k ep
  • K trans
  • Kinetic analysis
  • signal-enhancement ratio

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Distinguishing benign and malignant breast tumors : Preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. / Sorace, Anna G.; Partridge, Savannah C.; Li, Xia; Virostko, Jack; Barnes, Stephanie L.; Hippe, Daniel S.; Huang, Wei; Yankeelov, Thomas E.

In: Journal of Medical Imaging, Vol. 5, No. 1, 011019, 01.01.2018.

Research output: Contribution to journalArticle

@article{ba4592c1b3aa4932b8a5d44cd667ff4e,
title = "Distinguishing benign and malignant breast tumors: Preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial",
abstract = "Comparative preliminary analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data collected in the International Breast MR Consortium 6883 multicenter trial was performed to distinguish benign and malignant breast tumors. Prebiopsy DCE-MRI data from 45 patients with suspicious breast lesions were obtained. Semiquantitative mean signal-enhancement ratio (SERmean) was calculated for all lesions, and quantitative pharmacokinetic, parameters Ktrans, kep, and ve, were calculated for the subset with available T1 maps (n=35). Diagnostic performance was estimated for DCE-MRI parameters and compared to standard clinical MRI assessment. Quantitative and semiquantitative metrics discriminated benign and malignant lesions, with receiver operating characteristic area under the curve (AUC) values of 0.71, 0.70, and 0.82 for Ktrans, kep, and SERmean, respectively (p<0.05). At equal 94{\%} sensitivity, the specificity and positive predictive value of SERmean (53{\%} and 63{\%}, respectively) and K trans (42{\%} and 58{\%}) were higher than clinical MRI assessment (32{\%} and 54{\%}). A multivariable model combining SERmean and clinical MRI assessment had an AUC value of 0.87. Quantitative pharmacokinetic and semiquantitative analyses of DCE-MRI improves discrimination of benign and malignant breast tumors, with our findings suggesting higher diagnostic accuracy using SERmean. SERmean has potential to help reduce unnecessary biopsies resulting from routine breast imaging.",
keywords = "breast cancer, dynamic contrast-enhanced MRI, k ep, K trans, Kinetic analysis, signal-enhancement ratio",
author = "Sorace, {Anna G.} and Partridge, {Savannah C.} and Xia Li and Jack Virostko and Barnes, {Stephanie L.} and Hippe, {Daniel S.} and Wei Huang and Yankeelov, {Thomas E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1117/1.JMI.5.1.011019",
language = "English (US)",
volume = "5",
journal = "Journal of Medical Imaging",
issn = "2329-4302",
publisher = "SPIE",
number = "1",

}

TY - JOUR

T1 - Distinguishing benign and malignant breast tumors

T2 - Preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial

AU - Sorace, Anna G.

AU - Partridge, Savannah C.

AU - Li, Xia

AU - Virostko, Jack

AU - Barnes, Stephanie L.

AU - Hippe, Daniel S.

AU - Huang, Wei

AU - Yankeelov, Thomas E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Comparative preliminary analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data collected in the International Breast MR Consortium 6883 multicenter trial was performed to distinguish benign and malignant breast tumors. Prebiopsy DCE-MRI data from 45 patients with suspicious breast lesions were obtained. Semiquantitative mean signal-enhancement ratio (SERmean) was calculated for all lesions, and quantitative pharmacokinetic, parameters Ktrans, kep, and ve, were calculated for the subset with available T1 maps (n=35). Diagnostic performance was estimated for DCE-MRI parameters and compared to standard clinical MRI assessment. Quantitative and semiquantitative metrics discriminated benign and malignant lesions, with receiver operating characteristic area under the curve (AUC) values of 0.71, 0.70, and 0.82 for Ktrans, kep, and SERmean, respectively (p<0.05). At equal 94% sensitivity, the specificity and positive predictive value of SERmean (53% and 63%, respectively) and K trans (42% and 58%) were higher than clinical MRI assessment (32% and 54%). A multivariable model combining SERmean and clinical MRI assessment had an AUC value of 0.87. Quantitative pharmacokinetic and semiquantitative analyses of DCE-MRI improves discrimination of benign and malignant breast tumors, with our findings suggesting higher diagnostic accuracy using SERmean. SERmean has potential to help reduce unnecessary biopsies resulting from routine breast imaging.

AB - Comparative preliminary analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data collected in the International Breast MR Consortium 6883 multicenter trial was performed to distinguish benign and malignant breast tumors. Prebiopsy DCE-MRI data from 45 patients with suspicious breast lesions were obtained. Semiquantitative mean signal-enhancement ratio (SERmean) was calculated for all lesions, and quantitative pharmacokinetic, parameters Ktrans, kep, and ve, were calculated for the subset with available T1 maps (n=35). Diagnostic performance was estimated for DCE-MRI parameters and compared to standard clinical MRI assessment. Quantitative and semiquantitative metrics discriminated benign and malignant lesions, with receiver operating characteristic area under the curve (AUC) values of 0.71, 0.70, and 0.82 for Ktrans, kep, and SERmean, respectively (p<0.05). At equal 94% sensitivity, the specificity and positive predictive value of SERmean (53% and 63%, respectively) and K trans (42% and 58%) were higher than clinical MRI assessment (32% and 54%). A multivariable model combining SERmean and clinical MRI assessment had an AUC value of 0.87. Quantitative pharmacokinetic and semiquantitative analyses of DCE-MRI improves discrimination of benign and malignant breast tumors, with our findings suggesting higher diagnostic accuracy using SERmean. SERmean has potential to help reduce unnecessary biopsies resulting from routine breast imaging.

KW - breast cancer

KW - dynamic contrast-enhanced MRI

KW - k ep

KW - K trans

KW - Kinetic analysis

KW - signal-enhancement ratio

UR - http://www.scopus.com/inward/record.url?scp=85041169613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041169613&partnerID=8YFLogxK

U2 - 10.1117/1.JMI.5.1.011019

DO - 10.1117/1.JMI.5.1.011019

M3 - Article

AN - SCOPUS:85041169613

VL - 5

JO - Journal of Medical Imaging

JF - Journal of Medical Imaging

SN - 2329-4302

IS - 1

M1 - 011019

ER -